Development of Opioid Receptor Models for Rational Design of Bifunctional Ligands
Development of Opioid Receptor Models for Rational Design of Bifunctional Ligands
批准号:
7687911
负责人:
Judith Varady Hobrath
金额:
$27.78万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-15 至 2012-07-31
关键词:
Absence of pain sensationAdverse effectsAffinityAgonistAnalgesicsAttenuatedBindingBinding SitesCharacteristicsClinical TreatmentComplexComputer SimulationCoupledDependenceDevelopmentDrug DesignG-Protein-Coupled ReceptorsGenerationsGenesGoalsHealthIndividualKnock-outKnowledgeLigand BindingLigandsMediatingMedicalMethodsModelingMorphineOpioidOpioid AnalgesicsOpioid ReceptorPainPerformancePersonal SatisfactionPharmaceutical ChemistryPharmaceutical PreparationsPropertyResearchSamplingSeriesStructural ModelsStructureTestingTherapeutic Agentsaddictionanalogbasechronic paincomputing resourcesdelta opioid receptordesignexpectationimprovedinsightknowledge basemu opioid receptorsnext generationnovelnovel strategiesnovel therapeuticspharmacophorephenylmorphanpreventpublic health relevancereceptorreceptor bindingscaffoldthree-dimensional modeling
中文摘要
描述(由申请人提供):阿片类药物仍然是治疗中至重度疼痛的主要药物。目前可用的阿片药物的镇痛作用是通过它们与mu阿片受体的激动剂相互作用介导的。这些激动剂阿片类镇痛药的使用受到一些严重副作用的严重限制,如耐受性和依赖性的发展以及潜在的成瘾。最近使用阿片受体亚型选择性拮抗剂和激动剂配体以及基因敲除研究的研究提供了令人信服的证据,表明阻断阿片受体可以减少或预防mu激动剂镇痛药的副作用,而不会降低其镇痛作用。这为发现具有混合激动剂/拮抗剂活性的新型非肽阿片配体提供了动力,因为具有这种特征的配体有可能成为减轻疼痛的新型治疗药物,而不会产生伴随的耐受性和依赖性副作用。目前针对这类混合功能配体设计的药物化学研究主要依赖于基于配体结构的方法。如果通过开发活性和非活性状态的受体结构模型来描述强效激动剂和拮抗剂结合的要求,这些药物设计工作将获得显著的优势。越来越多的计算资源的可用性,加上g蛋白偶联受体(gpcr)计算模型的进展,使得进一步探索配体结合的结构基础和阿片受体及其异聚物的激活,以及新一代阿片镇痛药的合理设计。为了实现这些长期目标,本文提出了一项研究工作,重点关注以下具体目标:(1)建立活性状态下的mu阿片受体和非活性状态下的δ阿片受体的三维模型,并使用增强的构象采样方法改进这些模型(2)通过配体-受体复合物的结构预测,开发用于mu受体的配体结合和激活以及δ受体的结合和拮抗剂活性的药物载体(3)在获得的知识基础上,设计,合成,通过改进的结合和活性谱来评估新的配体,并在实验确定的活性谱的基础上改进和评估模型。(4)探索mu-delta异二聚体复合物的结构建模,以深入了解这种相互作用赋予这些复合物的新的结合位点特征。因此,拟议的研究应加强我们对各种配体与这些受体相互作用的基础知识和理解,并加强设计和开发新的改进配体的前景,这些配体有可能成为无严重副作用的强效镇痛药物。公共卫生相关性:严重和慢性疼痛是一种使人衰弱的疾病,对许多人的健康和福祉产生巨大影响。虽然阿片类药物是有效的止痛药,但它们的普遍使用受到诸如耐受性和依赖性等副作用的严重限制。拟议的研究重点是阿片受体的计算建模,以便设计和发现新的,有效的阿片镇痛化合物,没有与当前药物相关的限制性副作用。
英文摘要
DESCRIPTION (provided by applicant): Opioids still remain the primary drugs for the treatment of moderate to severe pain. The analgesic effects of currently available opioid drugs are mediated through their agonist interaction with the mu opioid receptor. The use of these mu agonist opioid analgesics is severely restricted by a number of serious side effects such as development of tolerance and dependence and the potential for addiction. Recent research using opioid receptor subtype selective antagonist and agonist ligands as well as gene knock out studies have provided convincing evidence that the blockade of opioid delta receptors can diminish or prevent the side effects of mu agonist analgesics without diminishing their analgesic effects. This has provided an impetus for discovering novel nonpeptide opioid ligands possessing mixed mu agonist/delta antagonist activity since ligands endowed with such a profile have the potential of emerging as new therapeutic agents for alleviating pain without attendant tolerance and dependence side effects. Current medicinal chemistry research focusing on the design of such mixed function ligands primarily depend on ligand structure based approaches. These drug design efforts could gain a significant advantage if requirements of potent agonist and antagonist binding are delineated through development of structural models of the mu and delta receptor in the active and inactive states. The availability of increasing computational resources coupled with advances in computational modeling of G-protein coupled receptors (GPCRs) allows further exploration of the structural basis of ligand binding and activation of the opioid receptors and their heterooligomers and the rational design of new generation of opioid analgesics. To achieve these long-term goals, proposed herein is a research effort focusing on the following specific aims: (1) Develop a three dimensional models of the mu opioid receptor in the active state and delta opioid receptor in the inactive state and refine these models using enhanced conformational sampling methods (2) Develop pharmacophores for ligand binding and activation at mu receptors and binding and antagonist activity at delta receptors through structure predictions from ligand- receptor complexes (3) On the basis of the knowledge gained, design, synthesize, and evaluate new ligands with improved binding and activity profiles and refine and evaluate models on the basis of experimentally determined activity profiles and (4) Explore modeling the structures of mu-delta heterodimer complexes to gain insight into novel binding site characteristics that such interactions confer to these complexes. The proposed research therefore should enhance our fundamental knowledge and understanding of the interaction of various ligands with these receptors in addition to enhancing the prospect of designing and developing new improved ligands with the potential for emerging as potent analgesic drugs for pain relief devoid of severe side effects. PUBLIC HEALTH RELEVANCE: Severe and chronic pain is a debilitating medical condition that has a huge impact on the health and well-being of a large number of individuals. Although opioid drugs are potent pain relievers, their general use is severely restricted by side effects such as tolerance and dependence. The proposed research is focused on computational modeling of the opioid receptors to enable the design and discovery of new, potent opioid analgesic compounds devoid of the limiting side effects associated with the current medications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Design of multi-target D-Ala-D-Ala ligase ligands
-
批准号:8098979
-
项目类别:
-
资助金额:$32.03万
-
财政年份:2010
-
负责人:Judith Varady Hobrath
-
依托单位:
Design of multi-target D-Ala-D-Ala ligase ligands
-
批准号:7979299
-
项目类别:
-
资助金额:$24.94万
-
财政年份:2010
-
负责人:Judith Varady Hobrath
-
依托单位:
Development of Opioid Receptor Models for Rational Design of Bifunctional Ligands
-
批准号:7512750
-
项目类别:
-
资助金额:$27.26万
-
财政年份:2008
-
负责人:Judith Varady Hobrath
-
依托单位:
海外基金